Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SMD Rise PCLBKK:SMD100-R 59 Cash-to-Debt is 0.34 as of Mar. 2026, which is 71% below its 10-year median of 1.19. GuruFocus rates BKK:SMD100-R with a GF Score™ of 59/100 and a GF Value™ of ฿22.39. The stock has 6 warning signs investors should review. Among 120 Medical Distribution companies, SMD Rise PCL ranks worse than 64.17% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SMD Rise PCL's cash to debt ratio for the quarter that ended in Mar. 2026 was 0.34.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, SMD Rise PCLcouldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for SMD Rise PCL's Cash-to-Debt or its related term are showing as below:
BKK:SMD100-R'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.09 Med: 1.19 Max: 10.85
Current: 0.34
During the past 8 years, SMD Rise PCL's highest Cash to Debt Ratio was 10.85. The lowest was 0.09. And the median was 1.19.
BKK:SMD100-R's Cash-to-Debt is ranked worse than 64.17% of 120
companies
in the Medical Distribution industry
Industry Median: 0.625
vs BKK:SMD100-R: 0.34
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
SMD Rise PCL Cash-to-Debt Related Terms
SMD Rise PCL Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for SMD Rise PCL's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
BKK:SMD100-R vs MCK, COR, CAH: Cash-to-Debt Comparison
For the Medical Distribution subindustry, SMD Rise PCL's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SMD Rise PCL Cash-to-Debt vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, SMD Rise PCL's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where SMD Rise PCL's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SMD Rise PCL (BKK:SMD100-R) has a Cash-to-Debt of 0.34 as of Mar. 2026. This is 71% below median its historical median of 1.19. Over the past decade, SMD Rise PCL's Cash-to-Debt has ranged from 0.09 to 10.85. According to the industry distribution chart, SMD Rise PCL ranks #77 out of 120 companies in the Medical Distribution industry, placing it in the top 64.2%.
Is SMD Rise PCL's Cash-to-Debt too high?
SMD Rise PCL's current Cash-to-Debt of 0.34 is 71% below median its 10-year median of 1.19. Over the past 10 years, this metric has ranged from a low of 0.09 to a high of 10.85. The Medical Distribution industry median Cash-to-Debt is 0.63. SMD Rise PCL's value of 0.34 is 45.6% below this industry median. Based on the distribution chart, SMD Rise PCL ranks #77 out of 120 companies in the Medical Distribution industry, which is below the industry midpoint. Overall, SMD Rise PCL has a GF Score™ of 59/100, reflecting its overall financial health beyond just this single metric.
How does SMD Rise PCL's Cash-to-Debt compare to MCK and COR?
According to the Medical Distribution industry distribution chart, SMD Rise PCL ranks #77 out of 120 companies for Cash-to-Debt. This places SMD Rise PCL in the lower half of its industry. The industry median Cash-to-Debt is 0.63. SMD Rise PCL's value of 0.34 is 45.6% below this benchmark. Historically, SMD Rise PCL's own Cash-to-Debt has ranged from 0.09 to 10.85 over the past decade. While the company's 10-year median is 1.19 vs. the industry median of 0.63, SMD Rise PCL has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Medical Distribution company?
The median Cash-to-Debt among Medical Distribution companies is 0.63, based on 120 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. SMD Rise PCL's current Cash-to-Debt of 0.34 is 45.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Medical Distribution industry, the median Cash-to-Debt is 0.63 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. SMD Rise PCL's current Cash-to-Debt is 0.34, which is 71% below median its own 10-year median of 1.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is SMD Rise PCL stock overvalued right now?
SMD Rise PCL (BKK:SMD100-R) has a current Cash-to-Debt of 0.34. The stock's GF Value™ is ฿22.39, compared to a current price of ฿5.85 — trading 73.9% below its estimated fair value. The current Cash-to-Debt is 0.34, which is 71% below median its 10-year median of 1.19 and 45.6% below the Medical Distribution industry median of 0.63. SMD Rise PCL's overall GF Score™ is 59/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For SMD Rise PCL (BKK:SMD100-R), the current Cash-to-Debt is 0.34 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is SMD Rise PCL (BKK:SMD100-R) Overvalued in 2026?
Based on GuruFocus' analysis, SMD Rise PCL stock appears to be undervalued.
The current stock price of ฿5.85 is trading 73.9% below its estimated GF Value™ of ฿22.39.
Key valuation signals for BKK:SMD100-R:
Cash-to-Debt: 0.34 (71% below median its 10-year median of 1.19)
GF Value™: ฿22.39 vs. price of ฿5.85 (73.9% below fair value)
Industry Position: 45.6% below the Medical Distribution median (#77 of 120)
No single metric tells the full story. See the BKK:SMD100-R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Address222,222/1-2 Moo 1, Rattanathibet Road, West Inn Complex Building, 10th Floor, Bang Rak Yai Subdistrict, Bang Bua Thong District, Nonthaburi Province, Bangkok, THA, 11110
SMD Rise PCL, formerly Saintmed PCL is engaged in the import and distribution of medical devices and equipment, rental services for medical equipment, and providing services related to medical equipment. It operates in Thailand. The Group is engaged in three operating segments: Sale of medical devices and equipment, medical supplies, Services of medical equipment at sleep lab centers and repair services, and Revenue from rental of medical equipment at wellness centers and other services. The Group is managed and operates principally in Thailand.
59GF Score
Get the complete analysis for BKK:SMD100-R
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BKK:SMD100-R has been successfully added to your 
